On October 4, 2022 Aurobac Therapeutics SAS (Aurobac), reported the appointment of Florence Séjourné as Chief Executive Officer (Press release, Evotec, OCT 4, 2022, View Source [SID1234621661]). Aurobac is a joint venture recently created by Boehringer Ingelheim, Evotec SE and bioMérieux, focusing on the development of a new precision medicine approach, from diagnosis to cure to fight Antimicrobial Resistance (AMR).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Florence’s is an experienced biotech leader with outstanding strategic and operational acumen. The Board has great confidence in her to successfully set-up and lead Aurobac," said Frank Kalkbrenner, Ph.D., Co-Founder and Member of the Board of Aurobac. "We are excited to welcome Florence to Aurobac and look forward to her building a strong team under her leadership to put Aurobac on track for growth and success."
Mrs. Séjourné brings 25 years of biotech experience, most recently in leadership roles in the field of Antimicrobial Resistance (AMR). She is founder and board member of the BEAM Alliance, an association representing European biotechs developing new solutions to fight against AMR. Further she has been actively involved in advocating for biopharmaceutical small and medium-sized enterprise (SME) compatible policies with worldwide stakeholders to stimulate much needed innovation in AMR for the last 8 years.
She joins Aurobac from Da Volterra, where she served as CEO and brought the company from bench scientific concepts to late-clinical stage, developing products to protect the intestinal microbiota from the deleterious effects of antibiotics, including prevention of infections and antibacterial resistance. Prior to this role, Mrs Séjourné co-founded and worked as CBO/COO of Genfit (GNFT), a biotech company focused on metabolic and liver related diseases. She holds engineering and pharmaceutical sciences degrees from MINES ParisTech and the University of Illinois at Chicago.
"Aurobac has the remarkable ambition to become a worldwide leader in AMR innovation with a unique combination of the best capabilities of the three founding companies towards developing a new precision medicine approach, from diagnosis to cure" said Mrs. Séjourné. "I am thrilled to join the initiative next to the founding partners and transform this fantastic vision into new drugs for patients."